Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kay Tetzlaff

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
COPD|February 19, 2015
One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled AnalysisLorcan McGarvey, Dennis Niewoehner, Sheldon Magder, et al.
Medicine and Science in Sports and Exercise|March 3, 2010
Glossopharyngeal insufflation and pulmonary hemodynamics in elite breath hold diversMonika Eichinger, Stephan Walterspacher, Tobias Scholz, et al.
Pulmonary Pharmacology & Therapeutics|April 12, 2015
Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatmentIan P Hall, Andrew V Fowler, Abhya Gupta, et al.
The European Respiratory Journal|November 21, 2015
Lung function changes over time following withdrawal of inhaled corticosteroids in patients with severe COPDHelgo Magnussen, Kay Tetzlaff, Eric D Bateman, et al.
American Journal of Respiratory and Critical Care Medicine|March 18, 2017
Eosinophilia, Frequent Exacerbations, and Steroid Response in Chronic Obstructive Pulmonary DiseasePeter M A Calverley, Kay Tetzlaff, Claus Vogelmeier, et al.
The European Respiratory Journal|March 29, 2020
The natural history of progressive fibrosing interstitial lung diseasesKevin K Brown, Fernando J Martinez, Simon L F Walsh, et al.
The New England Journal of Medicine|September 9, 2014
Withdrawal of inhaled glucocorticoids and exacerbations of COPDHelgo Magnussen, Bernd Disse, Roberto Rodriguez-Roisin, et al.
The Lancet. Respiratory Medicine|April 13, 2016
Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trialHenrik Watz, Kay Tetzlaff, Emiel F M Wouters, et al.
American Journal of Respiratory and Critical Care Medicine|December 17, 2009
Safety and efficacy of an inhaled epidermal growth factor receptor inhibitor (BIBW 2948 BS) in chronic obstructive pulmonary diseasePrescott G Woodruff, Michael Wolff, Jens M Hohlfeld, et al.
The New England Journal of Medicine|May 22, 2019
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung DiseaseOliver Distler, Kristin B Highland, Martina Gahlemann, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
COPD|February 19, 2015
One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled AnalysisLorcan McGarvey, Dennis Niewoehner, Sheldon Magder, et al.
Medicine and Science in Sports and Exercise|March 3, 2010
Glossopharyngeal insufflation and pulmonary hemodynamics in elite breath hold diversMonika Eichinger, Stephan Walterspacher, Tobias Scholz, et al.
Pulmonary Pharmacology & Therapeutics|April 12, 2015
Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatmentIan P Hall, Andrew V Fowler, Abhya Gupta, et al.
The European Respiratory Journal|November 21, 2015
Lung function changes over time following withdrawal of inhaled corticosteroids in patients with severe COPDHelgo Magnussen, Kay Tetzlaff, Eric D Bateman, et al.
American Journal of Respiratory and Critical Care Medicine|March 18, 2017
Eosinophilia, Frequent Exacerbations, and Steroid Response in Chronic Obstructive Pulmonary DiseasePeter M A Calverley, Kay Tetzlaff, Claus Vogelmeier, et al.
The European Respiratory Journal|March 29, 2020
The natural history of progressive fibrosing interstitial lung diseasesKevin K Brown, Fernando J Martinez, Simon L F Walsh, et al.
The New England Journal of Medicine|September 9, 2014
Withdrawal of inhaled glucocorticoids and exacerbations of COPDHelgo Magnussen, Bernd Disse, Roberto Rodriguez-Roisin, et al.
The Lancet. Respiratory Medicine|April 13, 2016
Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trialHenrik Watz, Kay Tetzlaff, Emiel F M Wouters, et al.
American Journal of Respiratory and Critical Care Medicine|December 17, 2009
Safety and efficacy of an inhaled epidermal growth factor receptor inhibitor (BIBW 2948 BS) in chronic obstructive pulmonary diseasePrescott G Woodruff, Michael Wolff, Jens M Hohlfeld, et al.
The New England Journal of Medicine|May 22, 2019
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung DiseaseOliver Distler, Kristin B Highland, Martina Gahlemann, et al.
Pageof 7